Skip to content

Effects of uterus scar and maternal age on the dose-response relationship of oxytocin during cesarean section

Effects of uterus scar and maternal age on the dose-response relationship of oxytocin during cesarean section

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037971
Enrollment
Unknown
Registered
2020-09-08
Start date
2020-09-15
Completion date
Unknown
Last updated
2020-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective cesarean section

Interventions

eligible non scarred uterus group:Oxytocin infusion, oxytocin bolus, myometrium oxytocin receptor and a-SMA receptor on immunohistochemical analysis, isometric tension test of myometrial strip
Senile non scarred uterus group:Oxytocin infusion, oxytocin bolus, myometrium oxytocin receptor and a-SMA receptor on immunohistochemical analysis, isometric tension test of myometrial strip
eligible scarred uterus group:Oxytocin infusion, oxytocin bolus, myometrium oxytocin receptor and a-SMA receptor on immunohistochemical analysis, isometric tension test of myometrial strip
Senile scarred uterus group:Oxytocin infusion, oxytocin bolus, myometrium oxytocin receptor and a-SMA receptor on immunohistochemical analysis, isometric tension test of myometrial strip

Sponsors

Jiaxing University Affiliated women and children Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Objects of ASA I - II; 2. Subjects aged 18-50 years; 3. The subject of singleton pregnancy; 4. Subjects of non scar uterus, scar uterus; 5. Patients undergoing elective cesarean section; 6. The subject of abdominal transverse incision; 7. For patients with hemiplegia, the anesthesia plane is T4-T6.

Exclusion criteria

Exclusion criteria: 1. Pregnant women entering labor; 2. The subject of premature rupture of amnion; 3. Subjects allergic to oxytocin; 4. Patients with severe obstetric complications (gestational hypertension, preeclampsia); 5. Subjects of predicted high risk factors for postpartum hemorrhage (placental abnormalities, macrosomia, uterine fibroids, postpartum uterine atony and history of hemorrhagic disease); 6. Subjects with congenital and acquired coagulation dysfunction; 7. Subjects with thrombocytopenia (platelet count < 100 x 10 ^ 9).

Design outcomes

Primary

MeasureTime frame
Oxytocin dose;Estimate blood loss;Uterine constraction score;Side effects;Oxytocin effective dose in 50% of parturients (ED50) for adequate uterine tone;Oxytocin effective dose in 90% of parturients (ED90) for adequate uterine tone;

Countries

China

Contacts

Public ContactChangna Wei

Jiaxing University Affiliated Women and Children Hospital

544631360@qq.com+86 18267382732

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026